I'm not emotional, am I?

Why QBTS (D-Wave Quantum) Deserves a Spot on Your Watchlist in Late 2025

Why QBTS (D-Wave Quantum) Deserves a Spot on Your Watchlist in Late 2025

December 19, 2025 – If you're a momentum trader who sometimes lets emotion guide your picks (hey, we all do it), then D-Wave Quantum (NYSE: QBTS) might just be the stock that's tugging at your heartstrings right now. Trading around $24–$25 after a wild ride this year, QBTS has been one of the hottest – and most volatile – names in the quantum computing space. It's up hundreds of percent in 2025, backed by real commercial progress, fresh analyst love, and that irresistible "next big thing" vibe.

The Momentum Is Real – And It's Emotional

Let's be honest: QBTS isn't a boring blue-chip. It's a high-beta rocket ship in a sector that's exploding with hype. The stock has delivered massive swings – think 15%+ days on news drops – and right now, the sentiment is turning bullish again. Recent analyst initiations from heavyweights like Jefferies ($45 target), Wedbush (Outperform), and Mizuho have lit a fire under the shares. Add in partnerships, government-focused units, and growing real-world adoption, and it's easy to get that gut feeling: this one could run hard into 2026.

If you're like many retail traders who ride the wave on emotion, QBTS fits the bill perfectly – speculative, exciting, and full of catalyst potential.

Key Catalysts Heating Up

  • Commercial Traction: D-Wave's annealing quantum systems are already in production use for optimization problems in logistics, manufacturing, and finance. Revenue is growing fast, with customers shifting from proofs-of-concept to multi-year deals.
  • Government Push: A new dedicated U.S. federal business unit targets defense and national security – perfect timing amid rising quantum investments.
  • Analyst Buzz: Strong Buy consensus, with targets pointing to 50–100%+ upside from current levels.
  • Sector Tailwinds: Quantum peers like RGTI and IONQ are moving in sympathy, but D-Wave's practical, annealing approach gives it a unique edge for near-term wins.

Quick Swing Trade Scenarios (As of Mid-December 2025)

High risk, high reward – size small and use stops. These are speculative setups based on recent momentum and catalysts.

Scenario Entry Range Target Stop Loss Potential Return Timeframe Probability (Illustrative)
Bullish Breakout (Analyst-Driven Rally) $24–$26 $32–$35 $22 30–45% 1–4 weeks High (60–70%)
Momentum Extension (Quantum Sector Rotation) $25–$27 $40+ $23 50–80%+ 1–3 months Medium (40–50%)
Pullback Buy (Dip on Profit-Taking) $20–$22 $28–$30 $18 30–40% 2–6 weeks Medium-High (50–60%)
Bearish Reversal (Overvaluation Fade) Short above $28 $18–$20 $30 25–35% 1–4 weeks Low (20–30%)

Note: These scenarios are hypothetical examples based on market sentiment and publicly available information at the time of writing.

The Bottom Line

QBTS is pure speculative fuel for traders who thrive on emotion and momentum. It's not for the faint-hearted – drawdowns can be brutal – but with quantum computing heating up and D-Wave leading on practical applications, the upside feels electric. If you're eyeing a position, watch volume on breakouts and those analyst targets closely.

Quantum isn't going away... and neither is the excitement around QBTS. Trade smart, manage risk, and enjoy the ride.


Disclaimer: This article is for informational and educational purposes only and reflects personal opinions as of the date published. It does not constitute financial, investment, or trading advice, and should not be relied upon as such. The author is not a registered investment advisor.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Any forward-looking statements, price levels, targets, or probabilities discussed are illustrative and not predictions. Readers should conduct their own research and consider their individual financial situation before making any investment decisions.

Comments

Popular posts from this blog

WULF Moderate Risk High Potential For Return

ZKIN I'm Inn

INHD Inhibikase Therapeutics